Multiple Myeloma is relatively a rare disease. It accounts for approximately 1% of all cancers and 10% of all blood and bone marrow cancers. For more information on Multiple Myeloma, click here-https://bit.ly/2HKs5da
Sep 7, 2020• Articles
The Multiple Myeloma Market is expected to grow during the study period 2017-30 due to a rich and robust pipeline, increasing incidence,...
Jun 4, 2019• Business Consultant, DelveInsight's Drug Report, DelveInsight's Oncology based Reports, Notizia, Pharma Consultant
Sanofi’s Isatuximab combo extends lives in multiple myeloma Phase III trials of Sanofi’s investigational anti-CD38 monoclonal antibody,...
Mar 15, 2019• Articles
Multiple Myeloma, the second most common type of malignant cancer first being Non-Hodgkin lymphoma, is a type of cancer which is formed due...
Feb 26, 2019• Business Consultant, DelveInsight's Drug Report, DelveInsight's Indication Pipeline Reports, Notizia, Pharma Consultant
Vertex, CRISPR Therapeutics treated a patient using CRISPR In the very first, a patient diagnosed with Beta thalassemia was treated...
Your email address will not be published. Required fields are marked *